[KOREA HERALD]

S. Korea approves phase 2, 3 trials of Genencell’s COVID-19 treatment

South Korean biotech firm Genencell said Wednesday that the company received approval from the Ministry of Food and Drug Safety for mid- and late-stage trials of its COVID-19 treatment candidate ES16001.
ES16001 is an oral COVID-19 drug candidate made with natural ingredients extracted from the leaves of Elaeocarpus sylvestris native to Korea. Genencell has developed the treatment candidate in collaboration with the College of Life Sciences at Kyung Hee University.

http://news.koreaherald.com/view.php?ud=20211027000773&md=20211030003222_BL